What is Arg Medtech?
Arg Medtech is at the forefront of developing innovative cardiac ablation systems, with a primary focus on a novel, non-thermal Pulsed Field Ablation (PFA) technology. This cutting-edge system is engineered to offer substantial improvements over conventional thermal energy sources, aiming to enhance patient safety, treatment efficacy, and long-term outcomes for individuals suffering from atrial fibrillation. The company's strategic objective is to provide healthcare providers and physicians with advanced tools for managing heart arrhythmias, thereby elevating the standard of care in cardiovascular interventions.
How much funding has Arg Medtech raised?
Arg Medtech has raised a total of $58.5M across 1 funding round:
Series B
$58.5M
Series B (2024): $58.5M with participation from Gilde Healthcare and Advent Life Sciences
Key Investors in Arg Medtech
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across Venture & Growth, Private Equity in Healthcare, and Private Equity in Climate Solutions. They focus on businesses enabling better care at lower costs and addressing planetary challenges.
Advent Life Sciences
Advent Life Sciences is a leading trans-Atlantic venture capital firm focused on building innovative life sciences businesses in the UK, Europe, and the USA, specializing in early and mid-stage investments in companies developing first-in-class or best-in-class medicines and medical products.
What's next for Arg Medtech?
With the recent major enterprise-level funding, Arg Medtech is poised for accelerated growth and the scaling of its innovative PFA technology. This strategic backing is expected to fuel further research and development, facilitate clinical trials, and support the commercialization efforts for their advanced cardiac ablation systems. The company's focus on improving patient outcomes in atrial fibrillation treatment positions it for significant impact within the cardiovascular medical device market, potentially leading to broader adoption and enhanced patient care globally.
See full Arg Medtech company page
